California State University-Chico

COO and CFO at Humanigen

Austin, Texas, United States

Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms. We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection. The company’s immediate focus is to prevent or minimize the cytokine release syndrome that precedes severe lung dysfunction and ARDS in serious cases of SARS-CoV-2 infection. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. In addition, the company is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, bispecific or natural killer (NK) T cell engaging immunotherapy treatments to break the efficacy/toxicity linkage, including to prevent and/or treat graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Additionally, Humanigen and Kite, a Gilead Company, are evaluating lenzilumab in combination with Yescarta® (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma in a clinical collaboration. For more information, visit <a href="http://www.humanigen.com">www.humanigen.com</a>.

Humanigen

COO and CFO

Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient’s own immune cells to attack cancer. TIL cells are extracted from a patient’s own tumor tissue, expanded through a proprietary process, and infused back into the patient. After infusion, TIL reach tumor tissue, where they attack tumor cells. The company has completed dosing in the pivotal study in patients with metastatic melanoma and is currently conducting a pivotal study in patients with advanced cervical cancer. In addition, the company’s TIL therapy is being investigated for the treatment of patients with locally advanced, recurrent or metastatic cancers including head and neck and non-small cell lung cancer. A clinical study to investigate Iovance T cell therapy for blood cancers called peripheral blood lymphocyte (PBL) therapy is open to enrollment. For more information, please visit <a href="http://www.iovance.com">www.iovance.com</a>.

Iovance Biotherapeutics, Inc.

Chief Financial Officer

Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms.  We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection as well as the serious and potentially life-threatening CAR-T therapy-related side effects while preserving and potentially improving the efficacy of the CAR-T therapy itself, thereby breaking the efficacy/toxicity linkage. The company’s immediate focus is to prevent or minimize the cytokine storm that precedes severe lung dysfunction and ARDS in serious cases of SARS-CoV-2 infection and also in combining FDA-approved and development stage CAR-T therapies with lenzilumab, the company’s proprietary Humaneered®anti-human-GM-CSF immunotherapy, which is its lead product candidate.  A clinical collaboration with Kite, a Gilead Company, to evaluate the sequential use of lenzilumab with Yescarta®, axicabtagene ciloleucel, in a multicenter clinical trial in adults with relapsed or refractory large B-cell lymphoma is currently enrolling. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity.

Humanigen, Inc.

Board Member, Audit Committee Chairman

PAION Inc. is a wholly owned subsidiary of PAION AG.  PAION AG is a publicly-listed Specialty Pharma Company headquartered in Aachen, Germany with further sites in Cambridge, UK and New Jersey, US. The company has a track record of developing hospital-based treatments for which there is substantial unmet medical need. PAION’s strategy is to participate in the commercialization of Remimazolam and extend its business with a focus on anesthesia/critical care products. PAION Inc. is focused on the development of Remimazolam for procedural sedation for the US market and is currently in phase 3 clinical trials.

PAION Inc.

Board Member

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. Mr. Morris was responsible for managing the company's finance operations, corporate development, information systems, commercial strategy, joint steering committee and investor relations functions.  The Company's late-stage pipeline includes DSUVIAS (sufentanil sublingual tablet, 30 mcg), designed for the treatment of moderate-to-severe acute pain in medically supervised settings.  AcelRx has filed the NDA for DSUVIA and the MAA in 2017.  AcelRx intends to commercialize DSUVIA through its own sales force initially for use in the Emergency Department.  AcelRx's second product is Zalviso® (sufentanil sublingual tablet system), designed for the management of moderate-to-severe acute pain in adult patients in the hospital. Zalviso delivers 15 mcg sufentanil sublingually through a non-invasive delivery route via a pre-programmed, patient-controlled analgesia device. Zalviso is approved in the EU and is in phase 3 in the U.S. Grunenthal Group holds the rights for Zalviso in Europe and has launched Zalviso in 9 EU countries.

AcelRx Pharmaceuticals, Inc.

Chief Financial Officer, Head of Business Development

Chief Financial Officer, Senior Vice President Global Corporate Development and Finance - VIVUS Inc. (NASDAQ: VVUS) is a biopharmaceutical company focused on the development and commercialization of therapies to treat obesity and restore sexual health. VIVUS’ lead product is Qsymia, a proprietary oral treatment for obesity, was approved in July 2012 and launched in September 2012.  Our second product, STENDRA, a next generation PDE5i, was approved in April 2102.  In my nine years at VIVUS we have successfully received FDA approval for three products and EU approval for one of those products.  The company has tripled in size in the last year and we are now a fully integrated commercial pharmaceutical company. During my rein as CFO the market cap has increased five times to $1 billion.  Current responsibilities include finance, corporate development, IT, human resources, legal, and investor relations.  I have raised $750 million through 9 separate raises, including a recent $250 million convertible offering and a $110 royalty financing.  I have designed and implemented an effective investor relations program resulting in several new sell side analyst reports, and an increase in the institutional shareholders base.  I completed divestiture of the manufacturing facility and legacy product line.  I reorganized finance department and international corporate structure, implemented full Sarbanes Oxley controls and systems, and selected independent auditors and corporate counsel.  In the 2012 I led effort to recruit and hire over 100 new employees to install the commercial infrastructure.  In 2012 I assumed the Global Corporate Development activities and am lead our efforts to partner our products worldwide. I recently completed partnering agreement for the US rights to STENDRA worth over $300 million to VIVUS and a separate agreement for ROW rights worth over $60 million.

VIVUS, Inc

Senior Vice President Finance and Global Corporate Development, CFO

Member of the Office of the President, Chief Financial Officer and Sr. Vice President Finance, Manufacturing & Administration - Questcor Pharmaceuticals Inc. (AMEX: QSC now NASDAQ: QCOR) is a specialty pharmaceutical company focused on the development, acquisition and marketing of pharmaceutical products. The Company historically marketed five products in the US.  I was promoted to the Office of the President in August 2004 to assume leadership responsibilities of the entire organization upon departure of CEO.  Additional responsibilities include finance, manufacturing, regulatory, quality assurance, mergers and acquisitions, legal, corporate governance, investor relations, information systems, facilities, human resources, accounting and administration. Accomplishments include:•         Raised $24 million in private equity and debt over three years to finance acquisitions and growth•         Built company to obtain revenues in excess of $16M and EBITDA positive in 3 years•         Sourced, negotiated and closed acquisition of FDA approved product•         Established new disclosure and financial reporting systems to ensure compliance with Sarbanes Act•         Established quality relationships with specialty pharmaceutical/healthcare analysts and bankers•         Recruited and built current finance, contract manufacturing, regulatory and quality team•         Company spokesman at industry conferences and for analysts, investors and the media•         Completed five-year strategic plan

Questcor Pharmaceuticals

Sr Vice President, Finance, Manufacturing & Adminstration, CFO

Chief Financial Officer - InterPro was a provider of travel & expense reporting automation services to large corporations worldwide.  Its offerings include software, consulting and business process outsourcing services.  The Company had over 100 people in two divisions with combined revenue run rate of over $12 million with an annualized operating budget of $20 million.  Responsible for all financial, legal and administrative aspects of the Company. The travel & expense reporting division was rolled back into the parent corporation in the fall of 2001.

InterPro

Vice President Finance & Administration and Chief Financial Officer - RiboGene, Inc. (Amex: RBO) a publicly held biopharmaceutical company merged with Cypros Pharmaceuticals to become Questcor Pharmaceuticals (Amex: QSC).  The Company was pursuing the discovery and development of human pharmaceuticals.  Responsibilities and duties include managing a staff of 6 in finance, information systems, facilities, health & safety, human resources, intellectual property, corporate communications, legal, investor and public relations and administration. •         Completed IPO for RiboGene in May 1998 (AMEX:RBO), One of nine biotech IPO's in 1998•         Raised over $50 million (private $30 million from VC's, public $20 million)•         Second in command behind Chief Executive Officer•         Provide business development, financial and negotiation support for all strategic alliances•         Company spokesman at industry conferences and for analysts, investors and the media•         Built operational infrastructure to support a 100% growth in headcount•         Responsible for construction of and relocation to a new state-of-the-art facility

Timothy Morris

Timothy Morris